Clinical Trials Browser

Phase 2 × INDUSTRY × tipifarnib × Clear all

NCT02807272 2024-07-17

CMML/AML

Phase 2 Completed

44 enrolled 17 charts

Other hematologic neoplasm

Leukemia, Myelomonocytic, Chronic

NCT02383927 2024-07-11

Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

Phase 2 Completed

63 enrolled 19 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Thyroid Neoplasms

NCT02464228 2024-06-26

PTCL

Phase 2 Completed

65 enrolled 16 charts

Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral, Lymphoma, Extranodal NK-T-Cell

NCT03719690 2024-06-21

AIM-HN/SEQ-HN

Phase 2 Completed

296 enrolled 27 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00050141 2013-02-01

Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00354146 2011-02-01

A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.

Phase 2 Completed

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT00048503 2010-04-27

Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older

Phase 2 Completed

Other hematologic neoplasm

Leukemia, Myeloid, Acute